Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protein Profile of Multiple Myeloma-Derived Extracellular Vesicles for the Discovery of Novel Myeloma-Related Biomarkers.

Cancer science·2026
Same author

Rethinking On-Target Off-Tumor Toxicity as a Hematopoietic Continuum.

European journal of haematology·2026
Same author

Mechanisms of post-transplant AML relapse and therapeutic implications.

Bone marrow transplantation·2026
Same author

Ferroptosis in Lymphoproliferative Disorders.

Cells·2026
Same author

Bridging Randomized Trial Efficacy and Real-World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real-World Evidence for Individualized Care.

European journal of haematology·2026
Same author

Multiple Myeloma and the Illusion of the Evidence Pyramid.

European journal of haematology·2026

Related Experiment Video

Updated: Jun 28, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K

Momelotinib in myelofibrosis.

Antonella Bruzzese1, Enrica Antonia Martino1, Caterina Labanca1

  • 1Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.

Expert Opinion on Pharmacotherapy
|April 16, 2024
PubMed
Summary

Momelotinib (MMB) offers a promising treatment for myelofibrosis (MF), effectively improving anemia by targeting the JAK pathway. This JAK inhibitor demonstrates efficacy in reducing spleen size and symptoms with a favorable safety profile.

Keywords:
JAK inhibitorMomelotinibmyelofibrosistherapy

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.2K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K

Related Experiment Videos

Last Updated: Jun 28, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.2K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Myelofibrosis (MF) is a serious hematologic disorder marked by bone marrow fibrosis, low blood counts, enlarged spleen, and fatigue.
  • Current Janus kinase (JAK) inhibitors like ruxolitinib and fedratinib can worsen anemia, a significant challenge in MF treatment.
  • Persistent anemia often leads to treatment discontinuation in myelofibrosis patients.

Purpose of the Study:

  • To review Momelotinib (MMB), a novel JAK inhibitor with a unique mechanism for treating myelofibrosis.
  • To highlight MMB's potential in addressing anemia, a key unmet need in MF therapy.
  • To evaluate MMB's efficacy, safety, and role in both treatment-naïve and pre-treated MF patients.

Main Methods:

  • Review of clinical trials and scientific literature on Momelotinib (MMB) for myelofibrosis.
  • Analysis of MMB's mechanism of action, including JAK and ACVR1/ALK2 inhibition.
  • Comparison of MMB's safety and efficacy profile against other JAK inhibitors.

Main Results:

  • Momelotinib (MMB) effectively reduces spleen size and alleviates constitutional symptoms in MF patients.
  • MMB demonstrates significant improvement in anemia in both treatment-naïve and pre-treated MF populations.
  • MMB exhibits a favorable safety profile compared to existing JAK inhibitors, with reduced myelosuppression.

Conclusions:

  • Momelotinib (MMB) is a valuable therapeutic option for myelofibrosis, specifically addressing anemia.
  • MMB's unique mechanism offers a potential solution to the challenge of persistent anemia in MF.
  • Further research is exploring MMB's utility in acute myeloid leukemia and combination therapies.